Group Revenues in the First Quarter of 2011 Rise by 5.2 Percent to EUR
Adjusted EBITDA Margin Reaches 17.7 Percent Compared With 17.0 Percent
in the Prior-year Period
Tripling of net Income to EUR 7.1m and Earnings per Share to EUR 0.20
Acquisition in Brazil Accelerates Successful Expansion in the Emerging
DUESSELDORF, Germany, April 7 /CNW/ - Gerresheimer AG, one of the
leading global suppliers to the pharma and healthcare industry, got off
to a good start in the new financial year. "We continued on our
successful course in the new financial year. We expect particularly
strong growth over the coming years in the emerging countries. Our
latest acquisition of the Brazilian company Vedat strengthens our
position in the emerging markets and expands our product portfolio,"
says Uwe Rohrhoff, CEO of Gerresheimer AG.
Cross-reference: Press release including Group Key Figures is available
In the first quarter of the financial year 2011 (December 1, 2010 to
February 28, 2011) Gerresheimer substantially increased its revenues,
with a 5.2 percent rise to EUR 236.6m. At constant exchange rates the
growth rate was 2.9 percent. The main growth drivers were products like
pharma bottles, injection vials, ampoules, insulin pens and inhalers.
There was also a further rise in demand for cosmetics products.
In the first quarter of 2011 Gerresheimer increased its adjusted EBITDA
to EUR 41.8m, 9 percent up on the prior year. The adjusted EBITDA
margin improved by 0.7 percentage points on the prior year to 17.7
percent. Net income almost tripled to EUR 7.1m in the first quarter.
Earnings per share also improved substantially from EUR 0.06 to EUR
0.20. Net financial debt was reduced by EUR 84.4m in comparison with
the prior year to EUR 318.2m. In addition, Gerresheimer introduced
"The worldwide demand for medicines will continue to rise in the coming
years. Demographic change, increasing incidence of acute and chronic
diseases, growth of self-medication and the need for healthcare in the
emerging countries will contribute to this. These megatrends provide
the basis for our future growth. With our products and services we can
contribute to improving health and well-being," says Rohrhoff.
For the financial year 2011 Gerresheimer's guidance is that revenue
growth as reported including Vedat will be 7 to 8 percent This is
equivalent to revenue growth of 6 to 7 percent at constant exchange
rates. The company assumes unchanged that the adjusted EBITDA margin
will reach around 20%. In 2011 the company expects to invest around EUR
SOURCE Gerresheimer AG
For further information:
Jens Kuerten, Director Corporate Communication & Marketing, Telephone +49-211-6181-250, Fax +49-211-6181-241, E-mail firstname.lastname@example.org